[go: up one dir, main page]

PE20050945A1 - Ester de rapamicin-42 amorfo con el acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico y sus composiciones farmaceuticas - Google Patents

Ester de rapamicin-42 amorfo con el acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico y sus composiciones farmaceuticas

Info

Publication number
PE20050945A1
PE20050945A1 PE2004000844A PE2004000844A PE20050945A1 PE 20050945 A1 PE20050945 A1 PE 20050945A1 PE 2004000844 A PE2004000844 A PE 2004000844A PE 2004000844 A PE2004000844 A PE 2004000844A PE 20050945 A1 PE20050945 A1 PE 20050945A1
Authority
PE
Peru
Prior art keywords
ester
amorphous
hydroximethyl
hydroxy
solvent
Prior art date
Application number
PE2004000844A
Other languages
English (en)
Inventor
Eric J Benjamin
Muhammand Ashraf
Ashwinkumar Jain
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050945(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20050945A1 publication Critical patent/PE20050945A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMA AMORFA DEL ESTER DE RAPAMICIN-42 AMORFO CON EL ACIDO 3-HIDROXI-2-(HIDROXIMETIL)-2-METILPROPIONICO, EL CUAL FUE AISLADO Y CARACTERIZADO POR UNA CROMATOGRAFIA LIQUIDA DE ALTA CAPACIDAD (CLAC), DRX Y CALORIMETRIA DE ANALIISIS DIFERENCIAL(CAD). LA FORMA AMORFA ES POR LO MENOS TRES VECES MAS SOLUBLE QUE LA FORMA CRISTALINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION QUE COMPRENDE: a) LA EVAPORACION DE LA COMBINACION DEL ESTER AMORFO Y EL ACIDO, A PARTIR DE UNA SOLUCION QUE CONTIENE EL ESTER DE RAPAMICIN-42 CRISTALINO CON EL ACIDO 3-HIDROXI-2-(HIDROXIMETIL)-2-METILPROPIONICO Y UN AGENTE DISOLVENTE COMO ALCOHOL O ETER Y PUEDE SER DESHIDRATADO O CONTENER AGUA COMO METANOL, ETANOL O ISOPROPIL, LA TEMPERATURA DE EVAPORACION ES DE POR LO MENOS DE 20°C; b) ALTERNATIVAMENTE LA FORMA AMORFA ES OBTENIDA POR PRECIPITACION, MEDIANTE LA ADICION DE UN SOLVENTE DE PRECIPITACION DE LA DISOLUCION ANTERIOR, DONDE EL SOLVENTE DE PRECIPITACION ES AGUA O ALCANO COMO N-HEPTANO A UNA TEMPERATURA DE, O BAJO DE, APROXIMADAMENTE 50°C
PE2004000844A 2003-09-03 2004-09-01 Ester de rapamicin-42 amorfo con el acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico y sus composiciones farmaceuticas PE20050945A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49978903P 2003-09-03 2003-09-03

Publications (1)

Publication Number Publication Date
PE20050945A1 true PE20050945A1 (es) 2005-12-14

Family

ID=34272870

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000844A PE20050945A1 (es) 2003-09-03 2004-09-01 Ester de rapamicin-42 amorfo con el acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico y sus composiciones farmaceuticas

Country Status (25)

Country Link
US (2) US7271177B2 (es)
EP (1) EP1660081A1 (es)
JP (1) JP2007504226A (es)
KR (1) KR20060090803A (es)
CN (1) CN1874771A (es)
AR (1) AR045559A1 (es)
AU (1) AU2004270154A1 (es)
BR (1) BRPI0414066A (es)
CA (1) CA2536775A1 (es)
CO (1) CO5680426A2 (es)
CR (1) CR8293A (es)
EC (1) ECSP066473A (es)
GT (1) GT200400175A (es)
IL (1) IL173786A0 (es)
MX (1) MXPA06002123A (es)
NO (1) NO20061048L (es)
PA (1) PA8611201A1 (es)
PE (1) PE20050945A1 (es)
RU (1) RU2345999C2 (es)
SA (1) SA04250334B1 (es)
SG (1) SG145716A1 (es)
TW (1) TW200510428A (es)
UA (1) UA84881C2 (es)
WO (1) WO2005023254A1 (es)
ZA (1) ZA200601822B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG145716A1 (en) * 2003-09-03 2008-09-29 Wyeth Corp Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same
DK1701698T3 (da) * 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
US7268144B2 (en) 2004-04-14 2007-09-11 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
WO2006026531A1 (en) * 2004-08-27 2006-03-09 Cordis Corporation Solvent free amorphous rapamycin
EP1809247A1 (en) * 2004-09-29 2007-07-25 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
EP1856130A1 (en) 2005-02-09 2007-11-21 Wyeth a Corporation of the State of Delaware Cci-779 polymorph and use thereof
BRPI0619493A2 (pt) * 2005-12-07 2016-09-06 Wyeth Corp forma cristalina purificada de cci-779, processo para a purificação de cc-779, produto, método para monitorar a cristalização de cci-779, kit, composição farmacêutica, método para o tratamento de câncer, e, uso de um cci-779 purificado
KR20080077619A (ko) * 2005-12-07 2008-08-25 와이어쓰 라파마이신 42-에스테르 보로네이트로부터 라파마이신42-에스테르를 제조하는 가변적인 방법
CN101351702A (zh) * 2005-12-07 2009-01-21 惠氏公司 结晶雷帕霉素的制备方法以及使用差示扫描量热法测量雷帕霉素化合物结晶度的方法
CN101304970A (zh) * 2005-12-21 2008-11-12 卫材R&D管理有限公司 1，2-二氢吡啶化合物的无定形物
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) * 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20080234657A1 (en) * 2007-03-22 2008-09-25 Medtronic Vascular, Inc. Methods for contributing to cardiovascular treatments
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
US8852620B2 (en) 2007-07-20 2014-10-07 Medtronic Vascular, Inc. Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
CN102292078A (zh) 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
US20100227799A1 (en) * 2009-03-09 2010-09-09 Medtronic Vascular, Inc. Simultaneous photodynamic therapy and photo induced polymerization
JP5637568B2 (ja) * 2009-05-12 2014-12-10 コーセプト セラピューティクス， インコーポレイテッド 固体形態および調製のためのプロセス
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
AU2012204232A1 (en) 2011-01-07 2013-06-27 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
WO2015029066A1 (en) * 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
FI3848027T3 (fi) 2013-11-25 2023-05-04 Corcept Therapeutics Inc Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3600282A4 (en) 2017-03-31 2020-08-19 Corcept Therapeutics, Inc. GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF COLD CANCER
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
PT115056B (pt) * 2018-10-04 2021-12-10 Hovione Farm Sa Formas amorfas de agentes quelantes e seus métodos de preparação
CN113226389B (zh) 2018-11-14 2022-11-08 乐通公司 在经改性设备表面上具有药物洗脱涂层的医疗设备
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132023A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN113490496A (zh) 2019-02-22 2021-10-08 科赛普特治疗学股份有限公司 一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
KR20220113767A (ko) 2019-12-11 2022-08-16 코어셉트 쎄라퓨틱스 인코포레이티드 미리코릴란트로 항정신병약-유도 체중 증가를 치료하는 방법
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
CA2496332A1 (en) * 2002-09-17 2004-04-01 Wyeth Oral formulations
KR20060057605A (ko) * 2003-08-07 2006-05-26 와이어쓰 Ｃｃｉ-779의 위치선택적 합성 방법
SG145716A1 (en) 2003-09-03 2008-09-29 Wyeth Corp Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same
DK1701698T3 (da) 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779

Also Published As

Publication number Publication date
SG145716A1 (en) 2008-09-29
IL173786A0 (en) 2006-07-05
US7446111B2 (en) 2008-11-04
ZA200601822B (en) 2008-12-31
NO20061048L (no) 2006-05-24
ECSP066473A (es) 2006-10-10
PA8611201A1 (es) 2005-05-10
AR045559A1 (es) 2005-11-02
SA04250334B1 (ar) 2008-05-19
AU2004270154A1 (en) 2005-03-17
RU2345999C2 (ru) 2009-02-10
MXPA06002123A (es) 2006-05-17
KR20060090803A (ko) 2006-08-16
EP1660081A1 (en) 2006-05-31
US7271177B2 (en) 2007-09-18
US20080070950A1 (en) 2008-03-20
GT200400175A (es) 2005-04-18
WO2005023254A1 (en) 2005-03-17
BRPI0414066A (pt) 2006-10-24
RU2006110568A (ru) 2007-10-10
US20050049271A1 (en) 2005-03-03
TW200510428A (en) 2005-03-16
CN1874771A (zh) 2006-12-06
CR8293A (es) 2006-07-14
JP2007504226A (ja) 2007-03-01
CA2536775A1 (en) 2005-03-17
CO5680426A2 (es) 2006-09-29
UA84881C2 (ru) 2008-12-10

Similar Documents

Publication Publication Date Title
PE20050945A1 (es) Ester de rapamicin-42 amorfo con el acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico y sus composiciones farmaceuticas
BR0318651A (pt) processo melhorado para preparar ésteres alquil de ácido graxo usado como biodiesel
Beroza Alkaloids from Tripterygium wilfordii Hook.—Wilforine and Wilfordine1, 2
McBee et al. The Preparation and Properties of 3, 3, 3-Trifluoro-1, 2-epoxypropane1
BR112018015775B1 (pt) Método para produção de desodorante
US2970165A (en) Sulfate compounds
BR112015018307B1 (pt) utilização de ácido sulfônico para a recuperação de glicerol proveniente da reação de transesterificação de triglicerídeos
ES8507571A1 (es) Un procedimiento para preparar un 2-bromo-6 b, 9a-difluoro-11b, 17a, 21-trihidroxi-1, 4-pregnadien-3, 20-diona-17, 21-diester
Bu'Lock et al. Chemistry of the higher fungi. Part V. The structures of nemotinic acid and nemotin
JPS52133939A (en) Preparation of 2-substituted benzanilides
JPS5331639A (en) Preparation of benzyl benzoate
DK0516311T3 (da) Kemisk fremgangsmåde til fremstilling af trifluoracetaldehyd
Ziegler Photochemical destruction of vitamin B2 in milk
AR036018A1 (es) Proceso para aislar monohidrato de imipenem cristalino puro
JPS5538338A (en) Clathrate compound and its preparation
Bair et al. Identification of Alcohols and Alkyl Hydrogen Sulfates with S-Benzylthiuronium Chloride
JPS5424818A (en) Preparation of high purity maleic acid monoalcohol ester
JPS5687589A (en) Preparation of dried phosphoric acid ester salt
JPS5424826A (en) Preparation of salt of alcohol sulfuric acid ester
JPS5296692A (en) Production of sodium polyacrylate
JPS55161877A (en) Low freezing point composition
GB552036A (en) Process for the manufacture of sodium-d-pantothenate in crystalline form
JPS53149985A (en) Preparation of 5-fluorouracil derivatives
ES8204719A1 (es) Un procedimiento de preparacion de derivados de azabiciclo- hexano
BR112019009473A2 (pt) composição ácida para o tratamento de ácidos graxos

Legal Events

Date Code Title Description
FC Refusal